Research Applications & Benefits
- these were two identical phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials (reconnect studies) evaluating bremelanotide 1.75 mg subcutaneously for premenopausal women with hsdd. bremelanotide significantly increased sexual desire and reduced distress compared to placebo. common adverse events included nausea, flushing, and headache.
- Clinical Implication: these pivotal phase 3 reconnect studies demonstrated that bremelanotide significantly improved sexual desire and reduced associated distress in premenopausal women with hsdd, leading to its regulatory approval.
Mechanism of Action
https://www.endocrine-abstracts.org/ea/0077/ea0077oc1.1
Primary Research Areas
- Sexual Desire/Arousal Enhancement
- Hypoactive Sexual Desire Disorder (HSDD)
- Sexual Dysfunction (men & women)
- Melanocortin Receptor Agonism (MC3R, MC4R)
- Central Nervous System (CNS) Modulation
